



(11) **EP 3 473 619 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07D 401/14^(2006.01) A61K 31/4545^(2006.01)
A61P 35/00^(2006.01)

(48) Corrigendum issued on:
04.11.2020 Bulletin 2020/45

(45) Date of publication and mention
of the grant of the patent:
09.09.2020 Bulletin 2020/37

(21) Application number: **18204389.3**

(22) Date of filing: **06.11.2015**

(54) **AURORA A KINASE INHIBITOR**

AURORA-A-KINASE-INHIBITOR

INHIBITEUR DE KINASE AURORA A

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: **14.11.2014 US 201462079742 P**

(43) Date of publication of application:
24.04.2019 Bulletin 2019/17

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
15798602.7 / 3 218 366

(73) Proprietor: **ELI LILLY AND COMPANY**
Indianapolis, IN 46285 (US)

(72) Inventor: **Henry, James Robert**
Indianapolis, 46206-6288 (US)

(74) Representative: **Smith, Andrew George**
Eli Lilly and Company Limited
European Patent Operations
Lilly Research Centre
Erl Wood Manor
Windlesham, Surrey GU20 6PH (GB)

(56) References cited:
WO-A1-2009/104802 WO-A1-2013/129443

EP 3 473 619 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).